Gemphire Therapeutics, Inc.

Home » Gemphire Therapeutics, Inc.

Secondary

Gemphire Therapeutics, Inc.

They are a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH.

Symbol

GEMP

Last Closing Price
$8.63

Shares
2,860,000

Effective Date
February 8, 2018

Underwriters
Piper Jaffray

To view the prospectus for Gemphire Therapeutics, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253